- Targeted treatment and immunotherapy of advanced non-small cell lung cancer2022 | First Faculty of Medicine
- Lorlatinib in the treatment of non‑small cell lung cancer2020 | Publication without faculty affiliation
- KRAS mutations in non-small cell lung cancer and options of treatment2020 | First Faculty of Medicine
- Atezolizumab in the first line of treatment for non-squamous metastatic non-small cell lung cancer2019 | Second Faculty of Medicine
- Immunotherapy in small cell lung cancer2021 | Faculty of Medicine in Pilsen
- Radiotherapy in non-small-cell lung cancer 20162016 | Publication without faculty affiliation
- Novel therapeutic targets in non-small cell lung cancer.2011 | First Faculty of Medicine
- Developmental trends and treatment of non-small cell lung cancer2012 | Second Faculty of Medicine
- Pembrolizumab in the treatment of non-small-cell lung cancer2016 | Publication without faculty affiliation
- Non-small cell lung cancer often becomes a chronic disease due to precise medicine and personalized treatment2020 | Publication without faculty affiliation
- Present and new trends in the treatment of non-small cell lung cancer2016 | Publication without faculty affiliation
- Immunotherapy of small cell lung cancer2020 | Publication without faculty affiliation
- Advances in management of stage III non-small cell lung cancer2022 | First Faculty of Medicine
- Lorlatinib in the treatment of non-small cell lung cancer2021 | Publication without faculty affiliation
- Immunotherapy in the treatment of non-small cell lung cancer2017 | Faculty of Medicine in Pilsen
- Role of histology in the choice of treatment for advanced non-small-cell lung cancer2010 | Publication without faculty affiliation
- Gemcitabine/carboplatin in advanced non-small cell lung cancer2002 | First Faculty of Medicine, Third Faculty of Medicine
- Targeted therapy of non-small cell lung cancer2021 | Faculty of Medicine in Pilsen
- Amivantamab in non‐small cell lung cancer treatment2023 | Third Faculty of Medicine
- Immunotherapy in the first line treatment of non-small cell lung cancer2021 | Publication without faculty affiliation
- Erlotinib in the treatment of advanced non-small cell lung cancer - present experience and results in the Czech Repuiblic2018 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Nonsmall cell lung cancer with RET gene fusion2021 | Publication without faculty affiliation
- Novel therapeutic targets in non-small cell lung cancer2011 | First Faculty of Medicine
- Anaemia during chemoradiotherapy for advanced non-small cell lung cancer - correlation of incidence and clinical importance2002 | First Faculty of Medicine
- Durvalumab in the treatment of locally advanced unresectable non‑small cell lung cancer – case report2023 | First Faculty of Medicine, Third Faculty of Medicine
- Gefitinib - experience on biological targeted therapy of non-small-cell-lung cancer2004 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Durvalumab in the treatment of small cell lung cancer2020 | Faculty of Medicine in Pilsen
- Immunotherapy in the first line treatment of non-small cell lung cancer2020 | Faculty of Medicine in Pilsen
- Prognostic and predictive markers in non-small cell lung cancer (NSCLC) - 1st part Summary Prognostic and predictive markers in non-small cell lung cancer (NSCLC) - 1st part Summary Prognostic and predictive markers in non-small cell lung cancer (NSCLC) - 1st part Summary PrognostiPrognostic and predictive markers in non-small cell lung cancer (NSCLC) - 1st part Summary Prognostic and predictive markers in non-small cell lung cancer (NSCLC) - 1st part2019 | Faculty of Medicine in Pilsen
- Small cell lung cancer, current treatment and perspectives2023 | Faculty of Medicine in Pilsen